Precision Promise Platform Trial for Metastatic Pancreatic Cancer

Brief description of study

Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate multiple regimens in metastatic pancreatic cancer. The goal of the platform is to find effective therapies for pancreatic cancer. The platform will rapidly and efficiently test multiple novel drugs and combinations compared to standard of care therapy in first and second metastatic patients. Bayesian response-adaptive randomization will be used to assign patients to arms based on their performance in subtypes of the disease

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Metastatic Pancreatic Cancer,Pancreatic Cancer,Cancer
Age: - 99 Years
Gender: All

Age ≥ 18 years Male and Female Histologically or cytologically confirmed metastatic pancreatic adenocarcinoma (PDAC)

Updated on 09 Mar 2024. Study ID: 842508

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).